← Back to All US Stocks

SS Innovations International, Inc. (SSII) Fundamental Analysis & AI Grade 2026

SSII Nasdaq Surgical & Medical Instruments & Apparatus FL CIK: 0001676163
Updated This Month • Analysis: May 15, 2026 • SEC Data: 2026-03-31
Combined AI Grade
C
88% Confidence
N/A
C
88% Conf
Pending
Analysis scheduled

📊 SSII Key Takeaways

Revenue: $11.1M
Net Margin: -32.3%
Free Cash Flow: $-2.4M
Current Ratio: 2.54x
Debt/Equity: 0.00x
EPS: $-0.02
AI Grade: C with 88% confidence
SS Innovations International, Inc. (SSII) receives a C fundamental grade with 88% confidence from our AI analysis based on SEC 10-K filings. With revenue of $11.1M, net profit margin of -32.3%, and return on equity (ROE) of -6.6%, SS Innovations International, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete SSII stock analysis for 2026.

Is SS Innovations International, Inc. (SSII) a Good Investment?

Claude

SSII exhibits severe fundamental weakness with stagnant revenue (0% YoY growth), deep operating losses (-32.8% margin), and negative operating cash flow (-$2.3M annually). Despite marginal YoY profitability improvements and healthy 48% gross margins, the company remains fundamentally unprofitable and is burning cash unsustainably against a depleting $16M reserve base.

SS Innovations International, Inc. Key Strengths (SSII)

Claude
  • + Strong gross margin of 48% demonstrates viable core product economics
  • + Excellent near-term liquidity with 2.54x current ratio and $16M cash on balance sheet
  • + Clean balance sheet with zero long-term debt and no debt service burden

SSII Stock Risks: SS Innovations International, Inc. Investment Risks

Claude
  • ! Complete revenue stagnation at 0% YoY growth indicating lack of market traction or demand
  • ! Severe operating losses (-32.8% margin) with -$3.6M operating loss proving core business is unprofitable
  • ! Negative operating cash flow of -$2.3M annually consuming ~14% of cash reserves annually at unsustainable pace

Key Metrics to Watch

Claude
  • * Revenue growth rate - must achieve positive YoY growth to validate business model viability
  • * Operating margin trend - current -32.8% unsustainable; requires clear path to profitability
  • * Operating cash flow inflection - must turn positive to demonstrate sustainable operations without burning reserves

SS Innovations International, Inc. (SSII) Financial Metrics & Key Ratios

Revenue
$11.1M
Net Income
$-3.6M
EPS (Diluted)
$-0.02
Free Cash Flow
$-2.4M
Total Assets
$90.5M
Cash Position
$16.0M

💡 AI Analyst Insight

Strong liquidity with a 2.54x current ratio provides a solid financial cushion.

SSII Profit Margin, ROE & Profitability Analysis

Gross Margin 48.0%
Operating Margin -32.8%
Net Margin -32.3%
ROE -6.6%
ROA -4.0%
FCF Margin -21.3%

SSII vs Healthcare Sector: How SS Innovations International, Inc. Compares

How SS Innovations International, Inc. compares to Healthcare sector averages

Net Margin
SSII -32.3%
vs
Sector Avg 12.0%
SSII Sector
ROE
SSII -6.6%
vs
Sector Avg 15.0%
SSII Sector
Current Ratio
SSII 2.5x
vs
Sector Avg 2.0x
SSII Sector
Debt/Equity
SSII 0.0x
vs
Sector Avg 0.6x
SSII Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is SS Innovations International, Inc. Stock Overvalued? SSII Valuation Analysis 2026

Based on fundamental analysis, SS Innovations International, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-6.6%
Sector avg: 15%
Net Profit Margin
-32.3%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

SS Innovations International, Inc. Balance Sheet: SSII Debt, Cash & Liquidity

Current Ratio
2.54x
Quick Ratio
1.89x
Debt/Equity
0.00x
Debt/Assets
39.8%
Interest Coverage
-83.54x
Long-term Debt
N/A

SSII Revenue & Earnings Growth: 5-Year Financial Trend

SSII 5-year financial data: Year 2025: Revenue $42.5M, Net Income -$19.2M, EPS $-0.11.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: SS Innovations International, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.11 indicates the company is currently unprofitable.

SSII Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-21.3%
Free cash flow / Revenue

SSII Quarterly Earnings & Performance

Quarterly financial performance data for SS Innovations International, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $5.1M -$3.6M $-0.02
Q3 2025 $4.4M -$3.2M $-0.02
Q2 2025 $4.5M -$256.7K $0.00
Q1 2025 $3.6M -$5.7M $-0.03

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

SS Innovations International, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$2.3M
Cash generated from operations
Stock Buybacks
$26.0K
Shares repurchased (TTM)
Capital Expenditures
$54.2K
Investment in assets
Dividends
None
No dividend program

SSII SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for SS Innovations International, Inc. (CIK: 0001676163)

📋 Recent SEC Filings

Date Form Document Action
May 26, 2026 8-K ea0291683-8k_ssinnovations.htm View →
May 13, 2026 4 xslF345X06/ownership.xml View →
May 13, 2026 8-K ea0290453-8k_ssinnovations.htm View →
May 13, 2026 10-Q ea0289126-10q_ssinnova.htm View →
May 7, 2026 8-K ea0289626-8k_ssinnovations.htm View →

Frequently Asked Questions about SSII

What is the AI rating for SSII?

SS Innovations International, Inc. (SSII) has an AI grade of C with 88% confidence, based on fundamental analysis of SEC EDGAR filings.

What are SSII's key strengths?

Claude: Strong gross margin of 48% demonstrates viable core product economics. Excellent near-term liquidity with 2.54x current ratio and $16M cash on balance sheet.

What are the risks of investing in SSII?

Claude: Complete revenue stagnation at 0% YoY growth indicating lack of market traction or demand. Severe operating losses (-32.8% margin) with -$3.6M operating loss proving core business is unprofitable.

What is SSII's revenue and growth?

SS Innovations International, Inc. reported revenue of $11.1M.

Does SSII pay dividends?

SS Innovations International, Inc. does not currently pay dividends.

Where can I find SSII SEC filings?

Official SEC filings for SS Innovations International, Inc. (CIK: 0001676163) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is SSII's EPS?

SS Innovations International, Inc. has a diluted EPS of $-0.02.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is SSII's fundamental grade?

Based on our AI fundamental analysis in May 2026, SS Innovations International, Inc. has a C grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is SSII stock overvalued or undervalued?

Valuation metrics for SSII: ROE of -6.6% (sector avg: 15%), net margin of -32.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is SSII's AI grade for 2026?

Our dual AI analysis gives SS Innovations International, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is SSII's free cash flow?

SS Innovations International, Inc.'s operating cash flow is $-2.3M, with capital expenditures of $54.2K. FCF margin is -21.3%.

How does SSII compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -32.3% (avg: 12%), ROE -6.6% (avg: 15%), current ratio 2.54 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 15, 2026 | Data as of: 2026-03-31 | Powered by Claude AI